Biogen's U.S. commercial chief jumps ship for Sandoz; Amgen takes over most of Glaxo's Prolia marketing;

> Novartis ($NVS) has appointed Richard Frances, a former Biogen Idec ($BIIB) SVP of U.S. commercial operations, to head its Sandoz generics unit. Release

> Pfizer ($PFE) has promoted Monica Piñuela to lead its communications efforts in Spain. News

> Johnson & Johnson ($JNJ) has selected Cohn & Wolfe to support consumer and healthcare communications within the company's Nordic region. More

> Amgen ($AMGN) will take over the marketing of osteoporosis med Prolia from GlaxoSmithKline ($GSK) in areas including the EU, Switzerland, Norway, Russia and Mexico by Dec. 31. Story

> Virgo Consumer Health & Wellbeing has hired Matthew Coy as senior account director and Reena Patel as senior account manager. More

> InVentiv Health has named Michael Griffith as its EVP. Release

> ScripsAmerica ($SCRC) partner Global Pharma Hub has struck an agreement with Jestaw Pharmaceuticals for the Canadian marketing and distribution of RapiMed children's pain reliever and fever reducer. More

> Nutra Pharma ($NPHC) is launching a social media and telemarketing campaign for the distribution of OTC painkiller Nyloxin. Release

> Mannkind Pharma ($MNKD) has selected ADK Fortune as its creative agency. More

And Finally... Canada's provincial health ministers have agreed to ask for a face-to-face meeting with Vertex ($VRTX) to discuss a "fair price" for its cystic fibrosis med Kalydeco. More

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.